Related Experiment Videos
Peptichemio in advanced neuroblastoma
Insights
Peptichemio (PTC), a peptide-based chemotherapy, showed high initial response rates in children with advanced neuroblastoma. However, its long-term efficacy was limited by short remission durations and significant toxicity.
Area of Science:
- Oncology
- Pharmacology
- Pediatric Medicine
Background:
- Neuroblastoma is a common pediatric cancer.
- Effective treatments for advanced neuroblastoma are crucial.
- Peptichemio (PTC) is a synthetic peptide-based chemotherapy agent.
Purpose of the Study:
- To evaluate the efficacy and toxicity of Peptichemio (PTC) in previously untreated children with advanced neuroblastoma.
Main Methods:
- 18 children with advanced neuroblastoma received PTC intravenously at 1-1.5 mg/kg/day for 1-3 cycles.
- Treatment involved 5-6 consecutive days of administration per cycle.
Main Results:
- 92% of patients (11/12) showed objective and subjective improvement.
- Complete remission was achieved in 2 patients.
- Median remission duration was 4 months; median overall survival was 6 months.
- Primary toxicities included bone marrow depression, phlebosclerosis, nausea, vomiting, and alopecia.
Conclusions:
- PTC demonstrated high initial response rates in pediatric neuroblastoma.
- Long-term outcomes were limited by short remission duration and survival.
- Profound thrombocytopenia and severe phlebosclerosis restrict chronic PTC use.
Abstract:
Peptichemio (PTC) is a mixture of six synthetic peptides of m-L-phenylalanine mustard. It acts with both alkylating and antimetabolic effects, interfering with the synthesis of DNA, RNA, and proteins. PTC was administered iv to 18 previously untreated children with advanced neuroblastoma at a dose of 1-1.5 mg/kg/day for one to three cycles of 5-6 consecutive days each. Eleven of 12 patients (92%) experienced both objective and subjective improvement; complete remission was achieved in two of them. In spite of the high remission rate, the median duration of remission has been short (4 months) and the overall survival (median, 6 months) did not seem to be influenced by the use of PTC. The primary toxic effects were, in order of importance, bone marrow depression, phlebosclerosis, nausea and vomiting, and alopecia. Chronic use of PTC seems limited by two major factors: profound long-lasting thrombocytopenia and severe phlebosclerosis.